The rising incidence of scleroderma globally has spotlighted the urgent need for advanced therapeutics and diagnostics. Amidst challenging economic landscapes shaped by geopolitical instability and health crises, the scleroderma industry remains resilient, pushing forward with innovative treatments and increasing prevalence as key growth drivers. The comprehensive market study demonstrates a compound annual growth rate (CAGR) of 7.5% for the year 2023 and an expected CAGR of 6.6% over the subsequent four years. The global scleroderma market is poised for expansion, with predictions revealing a notable surge from $2 billion in 2022 to an estimated $2.78 billion by 2027. 30, 2024 (GLOBE NEWSWIRE) - The "Global Scleroderma Market Report 2023" report has been added to 's offering.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |